Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00586729 · ClinicalTrials.gov registry record · NA

Vashe Wound Therapy Study

A NA study of Burns, sponsored by Valleywise Health.

Completed
Registry status
NA
Development phase
23
Enrollment target
1
Study location

NCT00586729: Completed NA study of Burns, sponsored by Valleywise Health.

NCT00586729 is a NA study of Burns that has completed, run by Valleywise Health. The registered enrollment target is 23 participants, below the 83-participant average among 36 other Burns trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00586729, a NA study of Burns, has completed, sponsored by Valleywise Health.

COMPLETED
Registry status
NA
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate the efficacy, safety, and tolerability of topical Vashe™ Wound Therapy applied to gauze dressing every 6 hours or as necessary to keep dressing moist versus 5% Mafenide Acetate applied to gauze dressing every 6 hours or as necessary to keep dressing moist for a total treatment duration of 5 days.

Primary Outcome

Percentage area of graft viability at 14 days as determined by clinical assessment of revascularization, adherence of the graft to the wound bed and color

Conditions Studied

Interventions

  • DEVICE Vashe
  • DRUG Mafenide acetate

Study Locations (1)

Arizona

  • Maricopa Integrated Health System - Phoenix

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2009-07
Est. Completion 2010-11
Phase NA
Valleywise Health

9 total trials

What the finished NCT00586729 record still lists

NCT00586729 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 83-participant average among 36 other Burns trials with a reported enrollment target (72% lower).

The record links to 1 condition, with Burns appearing as the primary indexed condition, and to 2 interventions - of which Vashe is the first listed.

NCT00586729 reports a single indexed study location in Arizona.

Frequently Asked Questions

What is clinical trial NCT00586729 about?

NCT00586729 is a clinical study titled "Vashe Wound Therapy Study". This study will evaluate the efficacy, safety, and tolerability of topical Vashe™ Wound Therapy applied to gauze dressing every 6 hours or as necessary to keep dressing moist versus 5% Mafenide Acetate applied to gauze dressing every 6 hours or as necessary to keep dressing moist for a total treatme...

What is the current status of trial NCT00586729?

This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2009-07. Estimated completion is 2010-11.

What conditions does trial NCT00586729 study?

This clinical trial studies the following conditions: Burns.

What interventions are being tested in trial NCT00586729?

The interventions under investigation include: Vashe (DEVICE), Mafenide acetate (DRUG).

Who is sponsoring clinical trial NCT00586729?

This trial is sponsored by Valleywise Health, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00586729 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Burns

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00586729's enrollment target sits among peer trials

23 21st of 36 higher than 16 of 36 other Burns trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Burns trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00586729, the US trial registry maintained by the National Library of Medicine. NCT00586729 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.